Reported 2 days ago
Eli Lilly & Co. shares surged after its experimental weight-loss pill, orforglipron, showed results comparable to Novo Nordisk's Ozempic, with patients losing 16 pounds over 40 weeks. This could position Lilly as a leader in the growing obesity drug market, projected to reach $130 billion by the decade's end. Analysts believe orforglipron could be a potential blockbuster, especially as the company is quickly moving towards regulatory submissions for the oral medication.
Source: YAHOO